Prostate Cancer Early Detection, Version 1.2014

• DOI: 10.6004/jnccn.2014.0120
• Publication Date: 2017-04-14T16:05:47Z
• Authors: Peter R. Carroll; J. Kellogg Parsons; Gerald Andriole; Robert R. Bahnson; Daniel A. Barocas; William J. Catalona; Douglas M. Dahl; John W. Davis; Jonathan I. Epstein; Ruth B. Etzioni; Veda N. Giri; George P. Hemstreet; Mark H. Kawachi; Paul H. Lange; Kevin R. Loughlin; William Lowrance; Paul Maroni; James Mohler; Todd M. Morgan; Robert B. Nadler; Michael Poch; Chuck Scales; Terrence M. Shane...; Andrew J. Vickers; Robert Wake; Dorothy A. Shead; Maria Ho
• Keywords: Male; 2. Zero hunger; 03 medical and health sciences; 0302 clinical medicine; Population Surveillance; Age Factors; Humans; Prostatic Neoplasms; Early Detection of Cancer; Randomized Controlled Trials as Topic; 3. Good health

The NCCN Guidelines for Prostate Cancer Early Detection provide recommendations for men choosing to participate in an early detection program for prostate cancer. These NCCN Guidelines Insights highlight notable recent updates. Overall, the 2014 update represents a more streamlined and concise set of recommendations. The panel stratified the age ranges at which initiating testing for prostate cancer should be considered. Indications for biopsy include both a cutpoint and the use of multiple risk variables in combination. In addition to other biomarkers of specificity, the Prostate Health Index has been included to aid biopsy decisions in certain men, given recent FDA approvals.